Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer

被引：0
|
作者：
Tuerkmen, B.
Schmitt, M.
Schmalfeldt, B.
Trommler, P.
机构：
来源：
Electrophoresis | / 18卷 / 05期
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Mutational analysis of the genes encoding urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in advanced ovarian cancer
    Turkmen, B
    Schmitt, M
    Schmalfeldt, B
    Trommler, P
    Hell, W
    Creutzburg, S
    Graeff, H
    Magdolen, V
    ELECTROPHORESIS, 1997, 18 (05) : 686 - 689
  • [2] The role of the urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in breast cancer
    Takac, Iztok
    Cufer, Tanja
    Gorisek, Borut
    Cas-Sikosek, Nina
    Bali, Robert
    Bosilj, Damijana
    Borstnar, Simona
    Lampelj, Maja
    Ravnik, Maja
    Kavalar, Rajko
    Fokter, Nina
    Arko, Darja
    ZDRAVNISKI VESTNIK-SLOVENIAN MEDICAL JOURNAL, 2011, 80 (05): : 405 - 412
  • [3] Role of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (PAI-1) for prognosis in endometrial cancer
    Steiner, E.
    Pollow, K.
    Hasenclever, D.
    Schormann, W.
    Hermes, M.
    Schmidt, M.
    Puhl, A.
    Brulport, M.
    Bauer, A.
    Petry, I. B.
    Koelbl, H.
    Hengstler, J. G.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : 569 - 576
  • [4] Downregulation of urokinase-type plasminogen activator inhibitor (PAI-1) in pancreatic cancer
    Metzger, R.
    Warnecke-Eberz, U.
    Prenzel, K. L.
    Baldus, S. E.
    Brabender, J.
    Vallboehmer, D.
    Hoelscher, A. H.
    Schneider, P. M.
    EJC SUPPLEMENTS, 2006, 4 (06): : 27 - 27
  • [5] Urokinase-type plasminogen activator and its inhibitor PAI-1 as prognostic factors in cervical cancer
    Köhler, U
    Martin, R
    Pippig, S
    Horn, LC
    GEBURTSHILFE UND FRAUENHEILKUNDE, 1999, 59 (10) : 513 - 518
  • [6] Impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) on progression-free survival in thyroid cancer
    Herceg, G. Horvatic
    Herceg, D.
    Bence-Zigman, Z.
    Tomic-Brzac, H.
    Kusacic-Kuna, S.
    Kralik, M.
    Kulic, A.
    Dodig, D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S375 - S375
  • [7] Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors
    vanderBurg, MEL
    HenzenLogmans, SC
    Berns, EMJJ
    vanPutten, WLJ
    Klijn, JGM
    Foekens, JA
    INTERNATIONAL JOURNAL OF CANCER, 1996, 69 (06) : 475 - 479
  • [8] Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer
    Ito, H
    Yonemura, Y
    Fujita, H
    Tsuchihara, K
    Kawamura, T
    Nojima, N
    Fujimura, T
    Nose, H
    Endo, Y
    Sasaki, T
    VIRCHOWS ARCHIV, 1996, 427 (05) : 487 - 496
  • [9] Content of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in oral mucosa and inflamed periodontal tissue
    Deppe, Herbert
    Hohlweg-Majert, Bettina
    Hoelzle, Frank
    Kesting, Marco R.
    Wagenpfeil, Stefan
    Wolff, Klaus-Dietrich
    Schmitt, Manfred
    QUINTESSENCE INTERNATIONAL, 2010, 41 (02): : 165 - 171
  • [10] Prognostic significance of urokinase plasminogen activator (uPA) and its inhibitor (PAI-1) in breast cancer
    Vrbanec, D.
    Jelisavac-Cosic, S.
    Jakic-Razumovic, J.
    Mustac, E.
    Kuzmic-Prusac, I.
    EJC SUPPLEMENTS, 2004, 2 (03): : 180 - 181
12345